Genome-Wide Association Study of L-Arginine and Dimethylarginines Reveals Novel Metabolic Pathway for Symmetric Dimethylarginine

Background—Dimethylarginines (DMA) interfere with nitric oxide formation by inhibiting nitric oxide synthase (asymmetrical DMA [ADMA]) and L-arginine uptake into the cell (ADMA and symmetrical DMA [SDMA]). In prospective clinical studies, ADMA has been characterized as a cardiovascular risk marker, whereas SDMA is a novel marker for renal function and associated with all-cause mortality after ischemic stroke. The aim of the current study was to characterize the environmental and genetic contributions to interindividual variability of these biomarkers. Methods and Results—This study comprised a genome-wide association analysis of 3 well-characterized population-based cohorts (Framingham Heart Study [FHS; n=2992], Gutenberg Health Study [GHS; n=4354], and Multinational Monitoring of Trends and Determinants in Cardiovascular Disease Study [MONICA]/Cooperative Health Research in the Augsburg Area, Augsburg, Bavaria, Germany [KORA] F3 [n=581]) and identified replicated loci (DDAH1, MED23, Arg1, and AGXT2) associated with the interindividual variability in ADMA, L-arginine, and SDMA. Experimental in silico and in vitro studies confirmed functional significance of the identified AGXT2 variants. Clinical outcome analysis in 384 patients of the Leeds stroke study demonstrated an association between increased plasma levels of SDMA, AGXT2 variants, and various cardiometabolic risk factors. AGXT2 variants were not associated with poststroke survival in the Leeds study or were they associated with incident stroke in the Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) consortium. Conclusions—These genome-wide association study support the importance of DDAH1 and MED23/Arg1 in regulating ADMA and L-arginine metabolism, respectively, and identify a novel regulatory renal pathway for SDMA by AGXT2. AGXT2 variants might explain part of the pathogenic link between SDMA, renal function, and outcome. An association between AGXT2 variants and stroke is unclear and warrants further investigation.

[1]  T. Lehtimäki,et al.  Genome-wide association study on dimethylarginines reveals novel AGXT2 variants associated with heart rate variability but not with overall mortality. , 2014, European heart journal.

[2]  A. Khera,et al.  Symmetrical Dimethylarginine Predicts Mortality in the General Population: Observations From the Dallas Heart Study , 2013, Arteriosclerosis, thrombosis, and vascular biology.

[3]  R. Töpper,et al.  Symmetric dimethylarginine is a marker of detrimental outcome in the acute phase after ischaemic stroke: role of renal function. , 2012, Clinical science.

[4]  E. Demerath,et al.  A genome-wide association study of aging , 2011, Neurobiology of Aging.

[5]  Maria Blettner,et al.  Distribution and Categorization of Left Ventricular Measurements in the General Population: Results From the Population-Based Gutenberg Heart Study , 2010, Circulation. Cardiovascular imaging.

[6]  Sudha Seshadri,et al.  A meta-analysis of four genome-wide association studies of survival to age 90 years or older: the Cohorts for Heart and Aging Research in Genomic Epidemiology Consortium. , 2010, The journals of gerontology. Series A, Biological sciences and medical sciences.

[7]  D. Abramowicz,et al.  Genotype-phenotype correlation in primary hyperoxaluria type 1: the p.Gly170Arg AGXT mutation is associated with a better outcome. , 2010, Kidney international.

[8]  A. Carter,et al.  Symmetric dimethylarginine predicts all-cause mortality following ischemic stroke. , 2010, Atherosclerosis.

[9]  Ying Wang,et al.  Genomewide association study of leprosy. , 2009, The New England journal of medicine.

[10]  D. Murry,et al.  Human Alanine-Glyoxylate Aminotransferase 2 Lowers Asymmetric Dimethylarginine and Protects from Inhibition of Nitric Oxide Production* , 2009, The Journal of Biological Chemistry.

[11]  Xinli Hu,et al.  Vascular Endothelial-Specific Dimethylarginine Dimethylaminohydrolase-1–Deficient Mice Reveal That Vascular Endothelium Plays an Important Role in Removing Asymmetric Dimethylarginine , 2009, Circulation.

[12]  E. Schwedhelm,et al.  Asymmetric dimethylarginine (ADMA) as a prospective marker of cardiovascular disease and mortality--an update on patient populations with a wide range of cardiovascular risk. , 2009, Pharmacological research.

[13]  Stanley L Hazen,et al.  Targeted Metabolomic Evaluation of Arginine Methylation and Cardiovascular Risks: Potential Mechanisms Beyond Nitric Oxide Synthase Inhibition , 2009, Arteriosclerosis, thrombosis, and vascular biology.

[14]  Qingbo Xu,et al.  Asymmetric and symmetric dimethylarginines are of similar predictive value for cardiovascular risk in the general population. , 2009, Atherosclerosis.

[15]  Ricardo J Komotar,et al.  Genomewide Association Studies of Stroke. , 2009, Neurosurgery.

[16]  Y. Huang,et al.  Mediator MED23 links insulin signaling to the adipogenesis transcription cascade. , 2009, Developmental cell.

[17]  Sung Woo Kim,et al.  Arginine metabolism and nutrition in growth, health and disease , 2009, Amino Acids.

[18]  R. Vanholder,et al.  Role of symmetric dimethylarginine in vascular damage by increasing ROS via store-operated calcium influx in monocytes. , 2009, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[19]  Maristela L Onozato,et al.  Isoform-Specific Regulation by NG,NG-Dimethylarginine Dimethylaminohydrolase of Rat Serum Asymmetric Dimethylarginine and Vascular Endothelium-Derived Relaxing Factor/NO , 2007, Circulation research.

[20]  Manuel A. R. Ferreira,et al.  PLINK: a tool set for whole-genome association and population-based linkage analyses. , 2007, American journal of human genetics.

[21]  A. Carter,et al.  Predictive Variables for Mortality After Acute Ischemic Stroke , 2007, Stroke.

[22]  E. Schwedhelm,et al.  High-throughput liquid chromatographic-tandem mass spectrometric determination of arginine and dimethylated arginine derivatives in human and mouse plasma. , 2007, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[23]  P. Amouyel,et al.  Association of arginase 1 gene polymorphisms with the risk of myocardial infarction and common carotid intima–media thickness , 2007, Journal of Medical Genetics.

[24]  J. Cooke,et al.  Symmetric dimethylarginine (SDMA) as endogenous marker of renal function--a meta-analysis. , 2006, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[25]  R. Böger.  Asymmetric dimethylarginine (ADMA): A novel risk marker in cardiovascular medicine and beyond , 2006, Annals of medicine.

[26]  J. Leiper,et al.  The DDAH-ADMA-NOS Pathway , 2005, Therapeutic drug monitoring.

[27]  C. Stehouwer,et al.  Plasma asymmetric dimethylarginine (ADMA) concentration is independently associated with carotid intima-media thickness and plasma soluble vascular cell adhesion molecule-1 (sVCAM-1) concentration in patients with mild-to-moderate renal failure. , 2005, Kidney international.

[28]  C. Gieger,et al.  KORA-gen - Resource for Population Genetics, Controls and a Broad Spectrum of Disease Phenotypes , 2005, Gesundheitswesen (Bundesverband der Arzte des Offentlichen Gesundheitsdienstes (Germany)).

[29]  E. Schwedhelm,et al.  Liquid chromatography-tandem mass spectrometry method for the analysis of asymmetric dimethylarginine in human plasma. , 2005, Clinical chemistry.

[30]  L. Pearl,et al.  Crystal structure of alanine:glyoxylate aminotransferase and the relationship between genotype and enzymatic phenotype in primary hyperoxaluria type 1. , 2003, Journal of molecular biology.

[31]  B M Psaty,et al.  Antihypertensive drug therapies and the risk of ischemic stroke. , 2001, Archives of internal medicine.

[32]  A. Sali,et al.  Protein structure modeling for structural genomics , 2000, Nature Structural Biology.

[33]  V. Malashkevich,et al.  Crystal structures of dialkylglycine decarboxylase inhibitor complexes. , 1999, Journal of molecular biology.

[34]  Ian G. Charles,et al.  Identification of two human dimethylarginine dimethylaminohydrolases with distinct tissue distributions and homology with microbial arginine deiminases. , 1999, The Biochemical journal.

[35]  A. Carter,et al.  Platelet GP IIIa PlA and GP Ib variable number tandem repeat polymorphisms and markers of platelet activation in acute stroke. , 1998, Arteriosclerosis, thrombosis, and vascular biology.

[36]  L. Almasy,et al.  Multipoint quantitative-trait linkage analysis in general pedigrees. , 1998, American journal of human genetics.

[37]  J. Boucher,et al.  Inhibition of arginase in rat and rabbit alveolar macrophages by Nω‐hydroxy‐D,L‐indospicine, effects on L‐arginine utilization by nitric oxide synthase , 1997, British journal of pharmacology.

[38]  U. Förstermann,et al.  Interference of L-arginine analogues with L-arginine transport mediated by the y+ carrier hCAT-2B. , 1997, Nitric oxide : biology and chemistry.

[39]  C. Sander,et al.  Errors in protein structures , 1996, Nature.

[40]  W. Grody,et al.  Comparative properties of arginases. , 1996, Comparative biochemistry and physiology. Part B, Biochemistry & molecular biology.

[41]  T. Raghunathan,et al.  The risk of myocardial infarction associated with antihypertensive drug therapies. , 1995, JAMA.

[42]  J. Fukuto,et al.  Inhibition of rat liver arginase by an intermediate in NO biosynthesis, NG-hydroxy-L-arginine: implications for the regulation of nitric oxide biosynthesis by arginase. , 1994, Biochemical and biophysical research communications.

[43]  David C. Atkins,et al.  The risk of myocardial infarction associated with the combined use of estrogens and progestins in postmenopausal women. , 1994, Archives of internal medicine.

[44]  S. Moncada,et al.  Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure , 1992, The Lancet.

[45]  J. Bamford,et al.  Classification and natural history of clinically identifiable subtypes of cerebral infarction , 1991, The Lancet.

[46]  M. Kimoto,et al.  Dimethylarginine:pyruvate aminotransferase in rats. Purification, properties, and identity with alanine:glyoxylate aminotransferase 2. , 1990, The Journal of biological chemistry.

[47]  W. Kannel,et al.  An investigation of coronary heart disease in families. The Framingham offspring study. , 1979, American journal of epidemiology.

[48]  R. Bentall,et al.  Funding: LM received interdisciplinary funding from the Medical Research Council and Economic and Social Research Council. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. , 2012 .

[49]  H. Haller,et al.  SDMA is an early marker of change in GFR after living-related kidney donation. , 2011, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[50]  W. Durante.  Regulation of L-arginine transport and metabolism in vascular smooth muscle cells , 2007, Cell Biochemistry and Biophysics.

[51]  N. Guex,et al.  SWISS‐MODEL and the Swiss‐Pdb Viewer: An environment for comparative protein modeling , 1997, Electrophoresis.

[52]  B. Psaty,et al.  The risk of myocardial infarction associated with the combined use of estrogens and progestins in postmenopausal women. , 1994, Archives of internal medicine.

[53]  E. Benjamin,et al.  with The Framingham Offspring Study. , 2018 .